Chronic oral etoposide in the treatment of lung cancer

Russell DeVore, John Hainsworth, F. Anthony Greco, Kenneth Hande, David Johnson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Etoposide is used commonly to treat both small cell lung cancer and non-small cell lung cancer. It is usually administered intravenously over 3 to 5 consecutive days, and usually given in combination with cisplatin. Preclinical cellular and clinical pharmacokinetic studies have demonstrated that etoposide is schedule-dependent and is optimally administered at low doses over prolonged periods of time. Recent early phase clinical trials have demonstrated that oral etoposide can be administered safely for 14 to 21 consecutive days. This schedule has demonstrated outstanding activity in patients with both recurrent and previously untreated small cell lung cancer. Activity against non-small cell lung cancer has also been reported; response rates are similar to those seen with the most active single agents used in the treatment of the disease. Chronic oral etoposide also has the advantages of outpatient convenience and tolerable side effects. This overview discusses the role of chronic oral etoposide in the management of small cell lung cancer and non-small cell lung cancer. The scientific rationale, results of early phase clinical trials, ongoing research, and future directions regarding the chronic administration of this important antineoplastic drug are also reviewed.

Original languageEnglish (US)
Pages (from-to)28-35
Number of pages8
JournalSeminars in Oncology
Volume19
Issue number6 SUPPL. 14
StatePublished - 1992

Fingerprint

Etoposide
Lung Neoplasms
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Appointments and Schedules
Clinical Trials
Therapeutics
Antineoplastic Agents
Cisplatin
Outpatients
Pharmacokinetics
Research

ASJC Scopus subject areas

  • Oncology

Cite this

DeVore, R., Hainsworth, J., Greco, F. A., Hande, K., & Johnson, D. (1992). Chronic oral etoposide in the treatment of lung cancer. Seminars in Oncology, 19(6 SUPPL. 14), 28-35.

Chronic oral etoposide in the treatment of lung cancer. / DeVore, Russell; Hainsworth, John; Greco, F. Anthony; Hande, Kenneth; Johnson, David.

In: Seminars in Oncology, Vol. 19, No. 6 SUPPL. 14, 1992, p. 28-35.

Research output: Contribution to journalArticle

DeVore, R, Hainsworth, J, Greco, FA, Hande, K & Johnson, D 1992, 'Chronic oral etoposide in the treatment of lung cancer', Seminars in Oncology, vol. 19, no. 6 SUPPL. 14, pp. 28-35.
DeVore R, Hainsworth J, Greco FA, Hande K, Johnson D. Chronic oral etoposide in the treatment of lung cancer. Seminars in Oncology. 1992;19(6 SUPPL. 14):28-35.
DeVore, Russell ; Hainsworth, John ; Greco, F. Anthony ; Hande, Kenneth ; Johnson, David. / Chronic oral etoposide in the treatment of lung cancer. In: Seminars in Oncology. 1992 ; Vol. 19, No. 6 SUPPL. 14. pp. 28-35.
@article{f80d020eac334a18adadafc43329bfed,
title = "Chronic oral etoposide in the treatment of lung cancer",
abstract = "Etoposide is used commonly to treat both small cell lung cancer and non-small cell lung cancer. It is usually administered intravenously over 3 to 5 consecutive days, and usually given in combination with cisplatin. Preclinical cellular and clinical pharmacokinetic studies have demonstrated that etoposide is schedule-dependent and is optimally administered at low doses over prolonged periods of time. Recent early phase clinical trials have demonstrated that oral etoposide can be administered safely for 14 to 21 consecutive days. This schedule has demonstrated outstanding activity in patients with both recurrent and previously untreated small cell lung cancer. Activity against non-small cell lung cancer has also been reported; response rates are similar to those seen with the most active single agents used in the treatment of the disease. Chronic oral etoposide also has the advantages of outpatient convenience and tolerable side effects. This overview discusses the role of chronic oral etoposide in the management of small cell lung cancer and non-small cell lung cancer. The scientific rationale, results of early phase clinical trials, ongoing research, and future directions regarding the chronic administration of this important antineoplastic drug are also reviewed.",
author = "Russell DeVore and John Hainsworth and Greco, {F. Anthony} and Kenneth Hande and David Johnson",
year = "1992",
language = "English (US)",
volume = "19",
pages = "28--35",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 14",

}

TY - JOUR

T1 - Chronic oral etoposide in the treatment of lung cancer

AU - DeVore, Russell

AU - Hainsworth, John

AU - Greco, F. Anthony

AU - Hande, Kenneth

AU - Johnson, David

PY - 1992

Y1 - 1992

N2 - Etoposide is used commonly to treat both small cell lung cancer and non-small cell lung cancer. It is usually administered intravenously over 3 to 5 consecutive days, and usually given in combination with cisplatin. Preclinical cellular and clinical pharmacokinetic studies have demonstrated that etoposide is schedule-dependent and is optimally administered at low doses over prolonged periods of time. Recent early phase clinical trials have demonstrated that oral etoposide can be administered safely for 14 to 21 consecutive days. This schedule has demonstrated outstanding activity in patients with both recurrent and previously untreated small cell lung cancer. Activity against non-small cell lung cancer has also been reported; response rates are similar to those seen with the most active single agents used in the treatment of the disease. Chronic oral etoposide also has the advantages of outpatient convenience and tolerable side effects. This overview discusses the role of chronic oral etoposide in the management of small cell lung cancer and non-small cell lung cancer. The scientific rationale, results of early phase clinical trials, ongoing research, and future directions regarding the chronic administration of this important antineoplastic drug are also reviewed.

AB - Etoposide is used commonly to treat both small cell lung cancer and non-small cell lung cancer. It is usually administered intravenously over 3 to 5 consecutive days, and usually given in combination with cisplatin. Preclinical cellular and clinical pharmacokinetic studies have demonstrated that etoposide is schedule-dependent and is optimally administered at low doses over prolonged periods of time. Recent early phase clinical trials have demonstrated that oral etoposide can be administered safely for 14 to 21 consecutive days. This schedule has demonstrated outstanding activity in patients with both recurrent and previously untreated small cell lung cancer. Activity against non-small cell lung cancer has also been reported; response rates are similar to those seen with the most active single agents used in the treatment of the disease. Chronic oral etoposide also has the advantages of outpatient convenience and tolerable side effects. This overview discusses the role of chronic oral etoposide in the management of small cell lung cancer and non-small cell lung cancer. The scientific rationale, results of early phase clinical trials, ongoing research, and future directions regarding the chronic administration of this important antineoplastic drug are also reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0027058069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027058069&partnerID=8YFLogxK

M3 - Article

C2 - 1336897

AN - SCOPUS:0027058069

VL - 19

SP - 28

EP - 35

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 14

ER -